# NCT05184712 (NCT05184712)

> Phase 3 Clinical Study of AK112 for NSCLC Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05184712
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Akeso
- Conditions: Non-Squamous Non-small Cell Lung Cancer
- Interventions: Ivonescimab (SMT112 or AK112) Injection; Placebo Injection
- Enrollment: 322
- Primary outcome: Progression-free survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 9
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct05184712

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05184712", "email": "<work email>"}; the inbox owner confirms by the emailed link.